Search

Displaying results 4201 - 4210 of 10000 in total
  1. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  2. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  3. Drug

    1D09C3

    go.drugbank.com/drugs/DB05121
    Experimental

    1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC

  4. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis.

  5. Drug

    Bimoclomol

    go.drugbank.com/drugs/DB06258
    Experimental

    Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

  6. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.

  7. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Mast-cell stabilizers, first one approved being cromolyn sodium, are used in treatment of ocular hypersensitivity reactions such as vernal conjunctivitis.

    Synonyms: N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate
  8. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  9. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity. … Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids.

  10. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.